ORLANDO -- Patients with progressive pancreatic neuroendocrine tumors lived twice as long without progression when treated with sunitinib (Sutent) compared with placebo, data from a French clinical trial showed.
Median overall survival had not been reached in the sunitinib arm, but sunitinib treatment was associated with a 60% reduction in hazard ratio compared with placebo. More than 90% of patients in the sunitinib group remained alive at six months, Eric Raymond, MD, reported here at the Gastrointestinal Cancers Symposium.
Here is the concern in lab studies....on does sutnet fule mets....
Also, its important to clearly understand what happens when the drug stops working! It happened to me with another drug! hell!
renalcarcinoidguy 1 year ago
This is an interesting video...question and should have beeb disclosed, does Dr Raymond have a relationship with the company? That is always a concern for me...
btw, your hair turns silver white, not GREY......! I did pazopanib...
finally this md should have asked re: risks of VEGF inhibitors potentially spreading cancer when they stop working!
renalcarcinoidguy 1 year ago